{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:29Z","timestamp":1792788449592,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Adelaide University","id":[{"id":"https:\/\/ror.org\/028g18b61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The biodistributions of radiometalated peptides and small molecules are greatly influenced by the charge conferred by the metal-chelator complex. Careful fine-tuning of this charge thus represents an attractive method to optimise pharmacokinetic properties. For this to be an effective strategy, numerous suitable chelators must be available for a given radiometal; each possessing a different net charge. Herein we report the synthesis of 2-(4,7,10-tris(2-amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)pentanedioic acid (DOTAMGA), a bifunctional chelator for the\n                      <jats:sup>203\/212<\/jats:sup>\n                      Pb theranostic pair containing a single negative charge, previously unattainable with reported radiolead chelators. DOTAMGA was incorporated into a radiopharmaceutical targeting the melanocortin 1 receptor (MC1R), a receptor highly expressed by melanomas, and evaluated in vivo against the commonly used radiolead chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic amide (TCMC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      DOTAMGA was synthesised and conjugated to the MC1R targeting peptide MC1RL for subsequent investigation alongside TCMC-MC1RL. DOTAMGA-MC1RL and TCMC-MC1RL exhibited comparable affinity for MC1R in a series of competition binding assays with MC1R expressing cells. DOTAMGA-MC1RL was effectively labelled with\n                      <jats:sup>212<\/jats:sup>\n                      Pb and\n                      <jats:sup>203<\/jats:sup>\n                      Pb under standard radiolabelling conditions, and UV\u2013Vis experiments demonstrated more rapid Pb\n                      <jats:sup>2+<\/jats:sup>\n                      complexation than TCMC-MC1RL. Both\n                      <jats:sup>212<\/jats:sup>\n                      Pb-labelled compounds remained\u2009&gt;\u200990% intact after 24\u00a0h incubation in human serum. In B16F0 melanoma bearing C57BL\/6 mice, DOTAMGA-MC1RL exhibited reduced hepatic uptake compared to TCMC-MC1RL, though a reduction in tumour uptake and resulting tumour to organ uptake ratios were also observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      DOTAMGA represents a promising tool to optimise the pharmacokinetic properties of\n                      <jats:sup>203\/212<\/jats:sup>\n                      Pb radiopharmaceuticals, and is a useful addition to existing radiolead chelators on account of its unique charge.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41181-026-00473-9","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:45:25Z","timestamp":1783176325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synthesis and in vivo evaluation of a bifunctional, glutamic acid derived chelator for the 203\/212Pb theranostic pair"],"prefix":"10.1186","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-8966","authenticated-orcid":false,"given":"Jarred Michael","family":"Scaffidi-Muta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong Ching","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kryza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew David","family":"Abell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"473_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/s0969-8051(01)00241-4","volume":"28","author":"H Akizawa","year":"2001","unstructured":"Akizawa H, Arano Y, Mifune M, Iwado A, Saito Y, Mukai T, et al. Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides. Nucl Med Biol. 2001;28:761\u20138. https:\/\/doi.org\/10.1016\/s0969-8051(01)00241-4.","journal-title":"Nucl Med Biol"},{"key":"473_CR2","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.addr.2008.04.005","volume":"60","author":"H Akizawa","year":"2008","unstructured":"Akizawa H, Uehara T, Arano Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev. 2008;60:1319\u201328. https:\/\/doi.org\/10.1016\/j.addr.2008.04.005.","journal-title":"Adv Drug Deliv Rev"},{"key":"473_CR3","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1021\/jm201226w","volume":"54","author":"NM Barkey","year":"2011","unstructured":"Barkey NM, Tafreshi NK, Josan JS, De Silva CR, Sill KN, Hruby VJ, et al. Development of Melanoma-Targeted Polymer Micelles by Conjugation of a Melanocortin 1 Receptor (MC1R) Specific Ligand. J Med Chem. 2011;54:8078\u201384","journal-title":"J Med Chem"},{"key":"473_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2967\/jnumed.123.266388","volume":"65","author":"D Bauer","year":"2024","unstructured":"Bauer D, Carter LM, Atmane MI, De Gregorio R, Michel A, Kaminsky S, et al. 212Pb-pretargeted theranostics for pancreatic cancer. J Nucl Med. 2024;65:109. https:\/\/doi.org\/10.2967\/jnumed.123.266388.","journal-title":"J Nucl Med"},{"key":"473_CR5","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1021\/jm049579s","volume":"48","author":"M Cai","year":"2005","unstructured":"Cai M, Mayorov AV, Cabello C, Stankova M, Trivedi D, Hruby VJ. Novel 3D pharmacophore of \u03b1-MSH\/\u03b3-MSH hybrids leads to selective human MC1R and MC3R analogues. J Med Chem. 2005;48:1839\u201348. https:\/\/doi.org\/10.1021\/jm049579s.","journal-title":"J Med Chem"},{"key":"473_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780199637256.001.0001","volume-title":"Fmoc solid phase peptide synthesis: a practical approach","author":"W Chan","year":"1999","unstructured":"Chan W, White P. Fmoc solid phase peptide synthesis: a practical approach. Oxford University Press; 1999."},{"key":"473_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s0969-8051(99)00086-4","volume":"27","author":"LL Chappell","year":"2000","unstructured":"Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MW. Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb. Nucl Med Biol. 2000;27:93\u2013100. https:\/\/doi.org\/10.1016\/s0969-8051(99)00086-4.","journal-title":"Nucl Med Biol"},{"key":"473_CR8","first-page":"5649","volume":"60","author":"J Chen","year":"2000","unstructured":"Chen J, Cheng Z, Hoffman TJ, Jurisson SS, Quinn TP. Melanoma-targeting properties of 99mtechnetium-labeled cyclic \u03b1-melanocyte-stimulating hormone peptide analogues. Can Res. 2000;60:5649\u201358.","journal-title":"Can Res"},{"key":"473_CR9","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1039\/D0CS00556H","volume":"50","author":"BM Cooper","year":"2021","unstructured":"Cooper BM, Iegre J, O\u2019 Donovan DH, \u00d6lweg\u00e5rd Halvarsson M, Spring DR. Peptides as a platform for targeted therapeutics for cancer: peptide\u2013drug conjugates (PDCs). Chem Soc Rev. 2021;50:1480\u201394. https:\/\/doi.org\/10.1039\/D0CS00556H.","journal-title":"Chem Soc Rev"},{"key":"473_CR10","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/s0960-894x(00)00413-3","volume":"10","author":"KP Eisenwiener","year":"2000","unstructured":"Eisenwiener KP, Powell P, M\u00e4cke HR. A convenient synthesis of novel bifunctional prochelators for coupling to bioactive peptides for radiometal labelling. Bioorg Med Chem Lett. 2000;10:2133\u20135. https:\/\/doi.org\/10.1016\/s0960-894x(00)00413-3.","journal-title":"Bioorg Med Chem Lett"},{"key":"473_CR11","first-page":"887","volume":"46","author":"S Froidevaux","year":"2005","unstructured":"Froidevaux S, Calame-Christe M, Tanner H, Eberle AN. Melanoma targeting with DOTA-\u03b1-melanocyte-stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake. J Nucl Med. 2005;46:887.","journal-title":"J Nucl Med"},{"key":"473_CR14","doi-asserted-by":"publisher","unstructured":"Francisco D.C. Guerra Liberal JMOS, Stephen J. McMahon, Kevin M. Prise,. Targeted Alpha Therapy: Current Clinical Applications. Cancer Biotherapy and Radiopharmaceuticals. 2020;35:404\u201317. https:\/\/doi.org\/10.1089\/cbr.2020.3576.","DOI":"10.1089\/cbr.2020.3576"},{"key":"473_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1071\/CH21184","volume":"75","author":"ML Grieve","year":"2022","unstructured":"Grieve ML, Paterson BM. The evolving coordination chemistry of radiometals for targeted alpha therapy. Aust J Chem. 2022;75:65\u201388. https:\/\/doi.org\/10.1071\/CH21184.","journal-title":"Aust J Chem"},{"key":"473_CR13","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","volume":"4","author":"Group TATW","year":"2018","unstructured":"Group TATW. Targeted alpha therapy, an emerging class of cancer agents: a review. JAMA Oncol. 2018;4:1765\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4044.","journal-title":"JAMA Oncol"},{"key":"473_CR15","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.drudis.2012.07.002","volume":"17","author":"SJ Hosseinimehr","year":"2012","unstructured":"Hosseinimehr SJ, Tolmachev V, Orlova A. Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today. 2012;17:1224\u201332. https:\/\/doi.org\/10.1016\/j.drudis.2012.07.002.","journal-title":"Drug Discov Today"},{"key":"473_CR16","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1107\/s2053229618004631","volume":"74","author":"P Jurek","year":"2018","unstructured":"Jurek P, Kiefer GE, Fronczek FR. Crystal structures of two polymorphic forms of DOTAM-mono-acid dihydrate. Acta Crystallogr C Struct Chem. 2018;74:542\u20137. https:\/\/doi.org\/10.1107\/s2053229618004631.","journal-title":"Acta Crystallogr C Struct Chem"},{"key":"473_CR17","doi-asserted-by":"publisher","first-page":"TPS9612","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9612","volume":"42","author":"NI Khushalani","year":"2024","unstructured":"Khushalani NI, El-Haddad G, Gage KL, Budzevich M, Schell MJ, Moros EG, et al. First-in-human study of 225actinium mti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM). J Clin Oncol. 2024;42:TPS9612. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS9612.","journal-title":"J Clin Oncol"},{"key":"473_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010189","volume":"14","author":"KV Kokov","year":"2022","unstructured":"Kokov KV, Egorova BV, German MN, Klabukov ID, Krasheninnikov ME, Larkin-Kondrov AA, et al. 212Pb: production approaches and targeted therapy applications. Pharmaceutics. 2022;14:189. https:\/\/doi.org\/10.3390\/pharmaceutics14010189.","journal-title":"Pharmaceutics"},{"key":"473_CR19","doi-asserted-by":"publisher","unstructured":"Kumar K, Magerst\u00e4dt M, Gansow OA. Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta. J Chem Soc, Chem Commun. 1989:145\u20136. https:\/\/doi.org\/10.1039\/C39890000145.","DOI":"10.1039\/C39890000145"},{"key":"473_CR20","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00259-023-06494-9","volume":"51","author":"D Lee","year":"2024","unstructured":"Lee D, Li M, Liu D, Baumhover NJ, Sagastume EA, Marks BM, et al. Structural modifications toward improved lead-203\/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2024;51:1147\u201362. https:\/\/doi.org\/10.1007\/s00259-023-06494-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"473_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/op8002932","volume":"13","author":"SG Levy","year":"2009","unstructured":"Levy SG, Jacques V, Zhou KL, Kalogeropoulos S, Schumacher K, Amedio JC, et al. Development of a multigram asymmetric synthesis of 2-(R)-2-(4,7,10-Tris tert-butylcarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)-pentanedioic acid, 1-tert-butyl ester, (R)-tert-Bu4-DOTAGA. Org Process Res Dev. 2009;13:535\u201342. https:\/\/doi.org\/10.1021\/op8002932.","journal-title":"Org Process Res Dev"},{"key":"473_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020414","volume":"15","author":"M Li","year":"2023","unstructured":"Li M, Baumhover NJ, Liu D, Cagle BS, Boschetti F, Paulin G, et al. Preclinical evaluation of a lead specific chelator (PSC) conjugated to radiopeptides for 203Pb and 212Pb-based theranostics. Pharmaceutics. 2023;15:414. https:\/\/doi.org\/10.3390\/pharmaceutics15020414.","journal-title":"Pharmaceutics"},{"key":"473_CR23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.125.269707","author":"F Liu","year":"2025","unstructured":"Liu F, Monterosso ME, Boucher D, Shakti S, Li KC, Kim C, et al. Preclinical evaluation of [212Pb]Pb-ADVC001: a prostate-specific membrane antigen\u2013targeted \u03b1-therapy for prostate cancer. J Nucl Med. 2025. https:\/\/doi.org\/10.2967\/jnumed.125.269707.","journal-title":"J Nucl Med"},{"key":"473_CR24","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1167\/iovs.06-0090","volume":"48","author":"MN L\u00f3pez","year":"2007","unstructured":"L\u00f3pez MN, Pereda C, Ram\u00edrez M, Mendoza-Naranjo A, Serrano A, Ferreira A, et al. Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy. Invest Ophthalmol vis Sci. 2007;48:1219\u201327. https:\/\/doi.org\/10.1167\/iovs.06-0090.","journal-title":"Invest Ophthalmol vis Sci"},{"key":"473_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-37313-8","volume":"13","author":"BL McNeil","year":"2023","unstructured":"McNeil BL, Mastroianni SA, McNeil SW, Zeisler S, Kumlin J, Borjian S, et al. Optimized production, purification, and radiolabeling of the 203Pb\/212Pb theranostic pair for nuclear medicine. Sci Rep. 2023;13:10623. https:\/\/doi.org\/10.1038\/s41598-023-37313-8.","journal-title":"Sci Rep"},{"key":"473_CR26","volume":"65","author":"B McNeil","year":"2024","unstructured":"McNeil B, Merkens H, Lin K-S, Schaffer P, Ramogida C. Evaluation of the effect of bifunctional chelator choice on the biodistribution of [Pb-203]Pb-FAPI bioconjugates. J Nucl Med. 2024;65:242288.","journal-title":"J Nucl Med"},{"key":"473_CR27","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1158\/1078-0432.Ccr-05-0619","volume":"11","author":"Y Miao","year":"2005","unstructured":"Miao Y, Hylarides M, Fisher DR, Shelton T, Moore H, Wester DW, et al. Melanoma therapy via peptide-targeted \u03b1-radiation. Clin Cancer Res. 2005;11:5616\u201321. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-05-0619.","journal-title":"Clin Cancer Res"},{"key":"473_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ph16111622","volume":"16","author":"BJB Nelson","year":"2023","unstructured":"Nelson BJB, Wilson J, Andersson JD, Wuest F. Theranostic imaging surrogates for targeted alpha therapy: progress in production, purification, and applications. Pharmaceuticals (Basel). 2023;16:1622. https:\/\/doi.org\/10.3390\/ph16111622.","journal-title":"Pharmaceuticals (Basel)"},{"key":"473_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0020-1693(95)04708-5","volume":"239","author":"CG Pippin","year":"1995","unstructured":"Pippin CG, McMurry TJ, Brechbiel MW, McDonald M, Lambrecht R, Milenic D, et al. Lead(II) complexes of 1,4,7,10-tetraazacyclododecane-N,N\u2019,N\u2019\u2019,N\u2019\u2019\u2019-tetraacetate: solution chemistry and application to tumor localization with 203Pb labeled monoclonal antibodies. Inorg Chim Acta. 1995;239:43\u201351-43-51. https:\/\/doi.org\/10.1016\/0020-1693(95)04708-5.","journal-title":"Inorg Chim Acta"},{"key":"473_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1021\/acs.bioconjchem.3c00007","volume":"34","author":"SJ Raheem","year":"2023","unstructured":"Raheem SJ, Salih AK, Garcia MD, Sharpe JC, Toosi BM, Price EW. A systematic investigation into the influence of net charge on the biological distribution of radiometalated peptides using [(68)Ga]Ga-DOTA-TATE derivatives. Bioconjug Chem. 2023;34:549\u201361. https:\/\/doi.org\/10.1021\/acs.bioconjchem.3c00007.","journal-title":"Bioconjug Chem"},{"key":"473_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54149-3","volume":"9","author":"SS Rinne","year":"2019","unstructured":"Rinne SS, Dahlsson Leitao C, Gentry J, Mitran B, Abouzayed A, Tolmachev V, et al. Increase in negative charge of (68)Ga\/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules. Sci Rep. 2019;9:17710. https:\/\/doi.org\/10.1038\/s41598-019-54149-3.","journal-title":"Sci Rep"},{"key":"473_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2967\/jnumed.124.268345","volume":"66","author":"A Saidi","year":"2025","unstructured":"Saidi A, Stallons TA, Wong AG, Schatzmann AT, Soysal U, Torgue JJ. Side-by-side comparison of the in vivo performance of [212Pb]Pb-DOTAMTATE and other SSTR2-targeting compounds. J Nucl Med. 2025;66:391\u20137. https:\/\/doi.org\/10.2967\/jnumed.124.268345.","journal-title":"J Nucl Med"},{"key":"473_CR33","doi-asserted-by":"publisher","first-page":"5754","DOI":"10.1073\/pnas.77.10.5754","volume":"77","author":"TK Sawyer","year":"1980","unstructured":"Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77:5754\u20138. https:\/\/doi.org\/10.1073\/pnas.77.10.5754.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"473_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-025-00362-7","volume":"10","author":"JM Scaffidi-Muta","year":"2025","unstructured":"Scaffidi-Muta JM, Abell AD. 212Pb in targeted radionuclide therapy: a review. EJNMMI Radiopharm Chem. 2025;10:34. https:\/\/doi.org\/10.1186\/s41181-025-00362-7.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"473_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589\u2013608. https:\/\/doi.org\/10.1038\/s41573-020-0073-9.","journal-title":"Nat Rev Drug Discov"},{"key":"473_CR36","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1038\/s41401-022-00970-y","volume":"43","author":"H Shi","year":"2022","unstructured":"Shi H, Cheng Z. MC1R and melanin-based molecular probes for theranostic of melanoma and beyond. Acta Pharmacol Sin. 2022;43:3034\u201344. https:\/\/doi.org\/10.1038\/s41401-022-00970-y.","journal-title":"Acta Pharmacol Sin"},{"key":"473_CR37","first-page":"6352","volume":"49","author":"W Siegrist","year":"1989","unstructured":"Siegrist W, Solca F, Stutz S, Giuffr\u00e8 L, Carrel S, Girard J, et al. Characterization of receptors for \u03b1-melanocyte-stimulating hormone on human melanoma cells1. Cancer Res. 1989;49:6352\u20138.","journal-title":"Cancer Res"},{"key":"473_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175429","volume":"27","author":"C Stokke","year":"2022","unstructured":"Stokke C, Kvassheim M, Blakkisrud J. Radionuclides for targeted therapy: physical properties. Molecules. 2022;27:5429. https:\/\/doi.org\/10.3390\/molecules27175429.","journal-title":"Molecules"},{"key":"473_CR39","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.2967\/jnumed.118.217240","volume":"60","author":"NK Tafreshi","year":"2019","unstructured":"Tafreshi NK, Tichacek CJ, Pandya DN, Doligalski ML, Budzevich MM, Kil H, et al. Melanocortin 1 receptor\u2013targeted \u03b1-particle therapy for metastatic uveal melanoma. J Nucl Med. 2019;60:1124\u201333. https:\/\/doi.org\/10.2967\/jnumed.118.217240.","journal-title":"J Nucl Med"},{"key":"473_CR40","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1021\/acs.molpharmaceut.0c00640","volume":"17","author":"CJ Tichacek","year":"2020","unstructured":"Tichacek CJ, Tafreshi NK, Kil H, Engelman RW, Doligalski ML, Budzevich MM, et al. Biodistribution and multicompartment pharmacokinetic analysis of a targeted \u03b1 particle therapy. Mol Pharm. 2020;17:4180\u20138. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.0c00640.","journal-title":"Mol Pharm"},{"key":"473_CR41","doi-asserted-by":"publisher","first-page":"15596","DOI":"10.1021\/acsomega.2c00387","volume":"7","author":"M Tosato","year":"2022","unstructured":"Tosato M, Lazzari L, Marco D. Revisiting Lead(II)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid coordination chemistry in aqueous solutions: evidence of an underestimated thermodynamic stability. ACS Omega. 2022;7:15596\u2013602. https:\/\/doi.org\/10.1021\/acsomega.2c00387.","journal-title":"ACS Omega"},{"key":"473_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/1536012117737919","volume":"16","author":"C Zhang","year":"2017","unstructured":"Zhang C, Lin K-S, B\u00e9nard F. Molecular imaging and radionuclide therapy of melanoma targeting the melanocortin 1 receptor. Mol Imaging. 2017;16:1536012117737919. https:\/\/doi.org\/10.1177\/1536012117737919.","journal-title":"Mol Imaging"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00473-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00473-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00473-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:59:01Z","timestamp":1790557141000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41181-026-00473-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["473"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00473-9","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"3 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"72"}}